LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Kidney Transplant Patients Identified at High Risk of Rejection

By LabMedica International staff writers
Posted on 18 Nov 2014
A quantitative real-time PCR (qPCR)-based assay can identify kidney transplant patients who are at high risk of acute rejection.

Minnie Sarwal at the University of California (San Francisco, CA, USA) and colleagues examined gene expression data from more than 430 renal transplant patients and developed a 17-gene set that could distinguish patients at high risk of rejection. They also developed an algorithm to classify patients into high- or low-risk categories using a numerical risk score.

Called kSORT for Kidney Solid Organ Response Test, the assay has the potential to become a simple, robust, and clinically applicable blood test, the scientists stated in their November 2014 PLOS Medicine paper.

In the US, there are some 17,000 kidney transplants a year, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the researchers noted that acute rejection occurs in some 15%–20% of patients even with immunosuppressive therapy. Currently, clinicians monitor creatinine levels as a marker for rejection, followed by a biopsy to confirm rejection. The new assay has a less invasive approach, and can identify rejection events early on.

A further seven genes were added to optimize the panel for both an adult and pediatric population. The 17 genes could predict 39 of 47 AR samples correctly as AR and 87 of 96 non-AR samples as non-AR, a sensitivity of nearly 83% and a specificity of just over 90%.

To develop the test, 558 blood samples from 436 adult and pediatric renal transplant patients in the US, Mexico, and Spain were collected. Using a set of 143 adult samples, the researchers found 31 genes that were differentially expressed between adult acute rejection (AR) and non-AR patients, as determined through kidney biopsies. A subset of 15 genes was able to classify nearly 92% of the AR and non-AR adult samples, but not in pediatric cases.

Related Links:

University of California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more